Linked lowest price!

On March 23, Chongqing, Inner Mongolia, Hubei, Sichuan, Yunnan, and Tibet provinces (autonomous regions and municipalities) issued the "Implementation Plan for the Continued Procurement of Drugs with the Expiration of the First and Third Batches of Centralized Procurement Agreements organized by the State (Draft for Comment)" , for public comment
.
The products to be successively purchased this time are the first and third batches of drugs that have expired under the centralized procurement agreement organized by the state.
Representatives from the six provinces and regions will form the Drug Alliance Procurement Office to represent the medical institutions in the six provinces (autonomous regions and municipalities) to implement the first and third batch of drugs.
The third batch of centralized procurement agreements organized by the state will continue to purchase drugs.
All public medical institutions (including military medical institutions) in the six provinces and regions will implement alliance-based procurement of related varieties, and other medical institutions are encouraged to actively participate
.
The specific catalog is as follows: The procurement cycle is two years in principle, and can be extended by one year if necessary
.
The purchase agreement is signed once a year during the purchase cycle
.
When renewing the purchase agreement, the agreed purchase volume shall in principle not be less than the agreed purchase volume of the selected drug in the previous year
.
If the agreed procurement volume is completed ahead of schedule within the procurement cycle, the excess selected companies will continue to supply at the selected price until the procurement cycle expires
.
This alliance's continuous procurement is carried out in the way of volume linkage and two-way selection.
The lowest selected price is linked to the national and provincial (including inter-provincial alliances) volume procurement.
Through mutual selection between buyers and sellers, the selected products are determined, and more than one can be selected
.
First of all, the company will make an independent quotation to determine the shortlisted pre-selected products
.
The medical institution comprehensively considers medication habits, supply security, etc.
, selects products within the scope of pre-selected products as the intended purchase products of the unit, and refers to the historical purchase volume, etc.
, and fills in 80% of the purchase demand in the next year (antibacterial drugs is 50%).
) as the agreed purchase quantity
.
If the products selected in the previous round purchased by a medical institution are included in the scope of pre-selected products, the agreed procurement volume must reach 50% of the agreed procurement volume of the medical institution
.
Then, the declaration enterprise will confirm whether it is supplied within the specified time based on its own supply capacity, and the products confirmed by the enterprise are the products to be selected.

.
If the enterprise has confirmed the supply of medical institutions in the alliance province, it shall not refuse to supply other medical institutions in the alliance province.
Such refusal is regarded as giving up the qualification for this participation
.
If the enterprise confirms that it does not supply or abandons the confirmation, the agreed purchase amount filled in by the corresponding medical institution will be pushed to the enterprise that has confirmed the supply and has the lowest price, that is, the two-way selection is completed
.
If the medical institution fails to fill in the product of the agreed purchase amount, the enterprise can also confirm the supply as the product to be selected
.
The product information to be selected will be released after publicity without objection
.
Push the agreed purchase volume of medical institutions, such as when there are multiple enterprises with the lowest price of the variety, they shall be determined in sequence according to the following rules: The original national centralized procurement company has priority; ); Enterprises that have passed or are deemed to have passed the consistency evaluation of the quality and efficacy of generic drugs by the State Drug Administration are preferred (subject to the approval date of the State Drug Administration); 2020 China Pharmaceutical Statistics Annual Report (Comprehensive Book) "In the "Industrial Enterprise Legal Persons Ranked by the Main Business Income of the Pharmaceutical Industry", the top-ranked enterprises are preferred
.
The official implementation plan is expected to be released in April
.